The efficacy and safety of tirofiban in patients with acute coronary syndromes with thrombus-containing lesions
- VernacularTitle:盐酸替罗非班对急性冠脉综合征并冠脉内血栓的疗效观察
- Author:
Daokuo YAO
;
Yuchen ZHANG
;
Lei WANG
- Publication Type:Journal Article
- Keywords:
Acute coronary syndromes;
Tirofiban;
Percutaneous coronary intervention
- From:
Chinese Journal of Practical Internal Medicine
2006;0(17):-
- CountryChina
- Language:Chinese
-
Abstract:
Objective The aim of our study was to evaluate the efficacy and safety of tirofiban in patients with acute coronary syndromes with thrombus-containing lesions.Methods We randomized 38 acute coronary syndromes(ACS)patients with thrombus-containing lesions into tirofiban group and control group.In the tirofiban group,10～30 mL of tirofiban was administered intracoronar before and/or after percutanous transluminal coronary angioplasty(PTCA),then stent was implanted as needed.Intravenous tirofiban was used for 24～48 hours after the procedure.In the control group,standard percutanous coronary intervention(PCI)was used for the patients.TIMI thrombosis grade,TIMI blood flow,no reflow and/or slow flow,corrected TIMI frame count(cTFC),myocardial blush grade(MBG),left ventricular eject fraction(LVEF)were measured in the two-dimensions untrasonography;major adverse cardiac events(MACE)and bleeding were observed.Results TIMI thrombosis grade and cTFC decreased more in the tirofiban group than that of the control group[0.90?0.14 vs 1.53?0.54,P
